Q-omics provides the consensus-scored RYR3 profile across patient tissues and cancer cell-line models. RYR3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RYR3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, RYR3 RNA expression shows 19,579 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BLCA, and UVM as cancer lineages where RYR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RYR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RYR3 survival associations across molecular data types. RYR3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RYR3 RNA expression–survival associations across cancer types. High RYR3 expression shows unfavorable associations in MESO, LGG, UVM and KIRC, but favorable associations in HNSC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for RYR3 RNA expression.
This table summarizes RYR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RYR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RYR3 shows lower tumor expression in BLCA, COAD, UCEC, KIRC, BRCA and STAD. The BLCA box plot shows higher RYR3 RNA expression in normal versus tumor tissue (log2 FC = −1.765, t-test p < 0.001).
This table shows molecular features associated with RYR3 in patient tissues and cancer cell lines. In patient samples, RYR3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RYR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
